{"id":68285,"date":"2026-06-16T13:55:47","date_gmt":"2026-06-16T05:55:47","guid":{"rendered":"https:\/\/flcube.com\/?p=68285"},"modified":"2026-06-16T13:55:48","modified_gmt":"2026-06-16T05:55:48","slug":"fosun-pharma-secures-nmpa-approval-for-fumaining-in-pediatric-langerhans-cell-histiocytosis-expands-mek-inhibitor-franchise","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68285","title":{"rendered":"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted approval for a <strong>supplemental New Drug Application (sNDA)<\/strong> for <strong>Fumaining (luvometinib)<\/strong>, extending its use to <strong>pediatric and adolescent patients aged 2 years and older<\/strong> with <strong>relapsed or refractory Langerhans cell histiocytosis (LCH)<\/strong> following systemic therapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Supplemental New Drug Application (sNDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Fumaining (luvometinib) \u2013 selective MEK1\/2 inhibitor<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Pediatric\/adolescent LCH (\u22652 years, relapsed\/refractory post-systemic therapy)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16 Jun 2026<\/td><\/tr><tr><td><strong>Existing Indications<\/strong><\/td><td>Adult LCH\/histiocytic neoplasms; pediatric NF1 with symptomatic inoperable PN<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Luvometinib \u2013 highly selective MEK1\/2 inhibitor<\/li>\n\n\n\n<li><strong>Target:<\/strong> MEK1\/2 kinases in the RAS\/RAF\/MEK\/ERK signaling pathway<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First MEK inhibitor approved in China for pediatric LCH; addresses significant unmet need in rare histiocytic disorders<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Additional sNDA for adult NF1 patients with symptomatic inoperable PN accepted by NMPA with priority review designation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-pipeline\" class=\"wp-block-heading\">Clinical Development Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Phase<\/th><th>Population<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Pediatric Low-Grade Glioma<\/strong><\/td><td>III<\/td><td>Children with progressive disease<\/td><td>Ongoing<\/td><\/tr><tr><td><strong>Extracranial Arteriovenous Malformation<\/strong><\/td><td>II<\/td><td>Patients with symptomatic lesions<\/td><td>Active<\/td><\/tr><tr><td><strong>KRAS-Mutant Advanced NSCLC<\/strong><\/td><td>II<\/td><td>Adults with confirmed KRAS mutations<\/td><td>Recruiting<\/td><\/tr><tr><td><strong>Adult NF1 with Inoperable PN<\/strong><\/td><td>&#8211;<\/td><td>Symptomatic patients<\/td><td>sNDA under priority review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The expanded approval for pediatric LCH builds on luvometinib&#8217;s established safety profile and demonstrates Fosun Pharma&#8217;s commitment to addressing rare diseases with high unmet medical needs across diverse age groups.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-significance\" class=\"wp-block-heading\">Market Impact &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare Disease Focus:<\/strong> LCH affects approximately 4\u20139 per million children annually in China, with limited treatment options for relapsed\/refractory cases<\/li>\n\n\n\n<li><strong>Franchise Expansion:<\/strong> This approval represents the third indication for Fumaining in China, strengthening Fosun&#8217;s position in targeted oncology therapies<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Luvometinib joins a select group of MEK inhibitors globally approved for histiocytic disorders, with potential differentiation through its pediatric formulation and dosing flexibility<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate peak annual sales of \u00a5800\u20131.2 billion (US$110\u2013165 million) across all indications by 2028, assuming 15\u201320% market penetration in addressable populations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Fosun Pharma&#8217;s continued investment in luvometinib&#8217;s clinical development reflects its strategy to build a diversified oncology portfolio targeting both common malignancies and rare histiocytic disorders with precision medicine approaches.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and commercial expectations for Fumaining (luvometinib). Actual results may differ due to risks including final regulatory decisions, clinical trial outcomes, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600196_20260616_1197.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20260616_1197.\"><\/object><a id=\"wp-block-file--media-cb6ff6d1-0bd6-4490-b229-15091488ab57\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600196_20260616_1197.pdf\">600196_20260616_1197<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/600196_20260616_1197.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-cb6ff6d1-0bd6-4490-b229-15091488ab57\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China&#8217;s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[159,893,15,24,892],"class_list":["post-68285","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-fosun-pharmaceutical","tag-hkg-2196","tag-product-approvals","tag-rare-orphan-disease-drugs","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval for a supplemental New Drug Application (sNDA) for Fumaining (luvometinib), extending its use to pediatric and adolescent patients aged 2 years and older with relapsed or refractory Langerhans cell histiocytosis (LCH) following systemic therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68285\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise\" \/>\n<meta property=\"og:description\" content=\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval for a supplemental New Drug Application (sNDA) for Fumaining (luvometinib), extending its use to pediatric and adolescent patients aged 2 years and older with relapsed or refractory Langerhans cell histiocytosis (LCH) following systemic therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68285\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T05:55:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T05:55:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68285#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68285\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise\",\"datePublished\":\"2026-06-16T05:55:47+00:00\",\"dateModified\":\"2026-06-16T05:55:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68285\"},\"wordCount\":418,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Fosun Pharmaceutical\",\"HKG: 2196\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68285#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68285\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68285\",\"name\":\"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-16T05:55:47+00:00\",\"dateModified\":\"2026-06-16T05:55:48+00:00\",\"description\":\"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China's National Medical Products Administration (NMPA) has granted approval for a supplemental New Drug Application (sNDA) for Fumaining (luvometinib), extending its use to pediatric and adolescent patients aged 2 years and older with relapsed or refractory Langerhans cell histiocytosis (LCH) following systemic therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68285#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68285\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68285#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China's National Medical Products Administration (NMPA) has granted approval for a supplemental New Drug Application (sNDA) for Fumaining (luvometinib), extending its use to pediatric and adolescent patients aged 2 years and older with relapsed or refractory Langerhans cell histiocytosis (LCH) following systemic therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68285","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise","og_description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China's National Medical Products Administration (NMPA) has granted approval for a supplemental New Drug Application (sNDA) for Fumaining (luvometinib), extending its use to pediatric and adolescent patients aged 2 years and older with relapsed or refractory Langerhans cell histiocytosis (LCH) following systemic therapy.","og_url":"https:\/\/flcube.com\/?p=68285","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-16T05:55:47+00:00","article_modified_time":"2026-06-16T05:55:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68285#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68285"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise","datePublished":"2026-06-16T05:55:47+00:00","dateModified":"2026-06-16T05:55:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68285"},"wordCount":418,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Fosun Pharmaceutical","HKG: 2196","Product approvals","Rare \/ orphan disease drugs","SHA: 600196"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68285#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68285","url":"https:\/\/flcube.com\/?p=68285","name":"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-16T05:55:47+00:00","dateModified":"2026-06-16T05:55:48+00:00","description":"Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China's National Medical Products Administration (NMPA) has granted approval for a supplemental New Drug Application (sNDA) for Fumaining (luvometinib), extending its use to pediatric and adolescent patients aged 2 years and older with relapsed or refractory Langerhans cell histiocytosis (LCH) following systemic therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68285#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68285"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68285#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis \u2013 Expands MEK Inhibitor Franchise"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68285"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68285\/revisions"}],"predecessor-version":[{"id":68287,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68285\/revisions\/68287"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}